Market Place
Sourcing Support
MILOS Study Highlights Bempedoic Acid`s Potential In Dyslipidemia
11 Oct 2024 //
EXPRESSPHARMA
MILOS German Cohort Results Show Increase In LDL-C Goal With
27 Sep 2024 //
BUSINESSWIRE
Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes
29 May 2024 //
BUSINESSWIRE
NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering
22 May 2024 //
BUSINESSWIRE
FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets
26 Apr 2024 //
FDA
FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexletol) Tablets
26 Apr 2024 //
FDA
Enforcement Report - Week of April 24, 2024
24 Apr 2024 //
FDA
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
22 Mar 2024 //
BUSINESSWIRE
FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
22 Mar 2024 //
BUSINESSWIRE
Enforcement Report - Week of September 13, 2023
13 Sep 2023 //
FDA
New secondary analysis of CLEAR data for bempedoic acid show risk reduction
26 Aug 2023 //
BUSINESSWIRE
Bempedoic acid significantly reduces the risk of adverse cardiovascular events
23 May 2023 //
BUSINESSWIRE
Esperion hits Nexletol partner Daiichi with lawsuit
28 Mar 2023 //
FIERCE PHARMA
Esperion in dispute with Daiichi over drug milestone payment
17 Mar 2023 //
BIOPHARMADIVE
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid
08 Dec 2022 //
BUSINESSWIRE
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL
08 Dec 2022 //
PRESS RELEASE
Kimia Biosciences Gets Permission For Bemopedoic Acid Bulk Drug; Stock Gains Near 3%
18 May 2022 //
INDIAINFOLINE
Zydus Lifesciences launches drug for treating bad cholesterol
13 May 2022 //
ECONOMIC TIMES
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data
02 May 2022 //
ESPERION
Esperion Supports Collaborative Study with NC to Study the Effects of NEXLIZET
25 Apr 2022 //
PRESS RELEASE
Esperion Publishes PIII Data on Bempedoic Acid in Journal of Clinical Lipidology
13 Apr 2022 //
PRESS RELEASE
Esperion Announces Two NEXLETOL Data Presentations at the ACC
03 Apr 2022 //
PRESS RELEASE
Esperion to cute 170 staffers as heart disease pill sputters
19 Oct 2021 //
YAHOOFINANCE
Esperion lays off nearly half its workforce as heart drug sales disappoint
18 Oct 2021 //
BIOPHARMADIVE
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
19 Mar 2021 //
PHARMATIMES
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination
17 Mar 2021 //
GLOBENEWSWIRE
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid)
16 Dec 2020 //
GLOBENEWSWIRE
Esperion`s new Nexletol analyses build its case with doctors
14 Nov 2020 //
FIERCE PHARMA
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations
13 Nov 2020 //
GLOBENEWSWIRE
NILEMDO® significantly lowers cholesterol in people with familial
08 Oct 2020 //
BUSINESSWIRE
Esperion launches DTC campaign for Nexletol with all-stock video
01 Oct 2020 //
FIERCE PHARMA
Daiichi Sankyo`s Nilemdo "significantly" reduces cholesterol levels at ESC 2020
01 Sep 2020 //
PHARMA FILE
Esperion Reports Second Quarter 2020 Financial Results and Provides Update
10 Aug 2020 //
GLOBENEWSWIRE
Esperion Announces Pooled Analysis from Ph3 LDL-C Lowering Devp of NEXLETOL
14 Jun 2020 //
GLOBENEWSWIRE
Esperion & Otsuka to develop treatment for hypercholesterolemia
22 Apr 2020 //
BIOSPECTRUMASIA
Esperion strikes Japan deal for `goldilocks` cholestrol drug, bags $60M cash
20 Apr 2020 //
COM
Esperion Therapeutics (ESPR) Announces EC Approval of NUSTENDI Tablet
06 Apr 2020 //
STREETINSIDER
Esperion`s Nexletol busts cholesterol levels regardless , ezitimibe therapy
30 Mar 2020 //
ESPERION
Esperion Announces Pooled Analyses from Ph3 LDL-C Lowering NEXLETOL™
23 Mar 2020 //
GLOBENEWSWIRE
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
28 Feb 2020 //
FIERCE PHARMA
Esperion gets FDA thumbs up for cholesterol drug Nexletol
26 Feb 2020 //
PMLIVE
Givlaari, Nubeqa among Jan CHMP decisions
03 Feb 2020 //
PHARMATIMES
Esperion Announces +ve CHMP Opinion for the Mkt Authorisation for Bempedoic Acid
31 Jan 2020 //
GLOBENEWSWIRE
CHMP issues +ve opinions for bempedoic acid and the bempedoic acid / ezetimib
31 Jan 2020 //
BUSINESSWIRE
Go or no go? Esperion`s double whammy and a look to priority reviews
31 Jan 2020 //
EVALUATE
Bempedoic Acid Lowers LDL-Cholesterol without affecting Glycaemic Control
18 Nov 2019 //
BUSINESS WIRE
Esperion’s Bempedoic Acid/ Ezetimibe Tablet Achieves Positive Phase II Results
02 Sep 2019 //
CONTRACT PHARMA
Esperion and Oberland Capital Announce $200 Million Funding Agreement
27 Jun 2019 //
BIOSPACE
Ph3 study of bempedoic acid demonstrates significant LDL-cholesterol lowering
03 Apr 2019 //
PHARMABIZ
Sangamo, Pfizer announce +ve ph 1/2 interim data for hemophilia A gene therapy
03 Apr 2019 //
PHARMABIZ
Esperion shares yo-yo as NEJM papers downplay cancer death data
15 Mar 2019 //
FIERCE BIOTECH
EMA validates Daiichi Sankyo & Esperion`s MAA for bempedoic acid
01 Mar 2019 //
PHARMABIZ
Daiichi Sankyo Europe & Esperion Announce Validation of MAA for Bempedoic Acid
28 Feb 2019 //
PR NEWSWIRE
Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
27 Aug 2018 //
FIERCE PHARMA
Esperion’s cholesterol drug cuts LDL-C in phase 3
27 Aug 2018 //
FIERCE BIOTECH
Esperion`s LDL drug aces a third pivotal trial
24 May 2018 //
FIERCE BIOTECH
